A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
A Clinical Study on the Safety and Effectiveness of targeting CD33 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia
BIOLOGICAL: CD33 CAR T-cells
Dose-limiting toxicity (DLT), Adverse events assessed according to NCI-CTCAE v5.0 criteria, Up to 28 days after Treatment|Incidence of treatment-emergent adverse events (TEAEs), Incidence of treatment-emergent adverse events \[Safety and Tolerability\], Up to 2 years after Treatment
Complete response (CR), and complete response with incomplete hematologic recovery (CRi), The proportion of patients with CR (complete response) /CRi (complete response with incomplete blood cell recovery) and PR (partial response)., Up to 12 weeks after CAR-T infusion|Duration of remission ,DOR, The time from CR/CRi and PR to disease relapsed or death due to disease progression after CAR-T infusion, Up to 1 years after CAR-T infusion|Overall survival, OS, The time from CAR-T infusion to death due to any cause, Up to 1 years after CAR-T infusion|Leukemia-Free Survival, LFS, The time from CAR-T infusion torecurrence or metastasis, Up to 2 years after Treatment
This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety and efficacy of CD33 CAR-T Cell in patients with relapsed or refractory acute myeloid leukemia. It is planned to enroll 15-27 participants in this trial.